Luteal phase sertraline treatment of premenstrual dysphoric disorder (PMDD): Effects on markers of hypothalamic pituitary adrenal (HPA) axis activation and inflammation
Barone J, Ho A, Osborne L, Eisenlohr-Moul T, Morrow A, Payne J, Epperson C, Hantsoo L. Luteal phase sertraline treatment of premenstrual dysphoric disorder (PMDD): Effects on markers of hypothalamic pituitary adrenal (HPA) axis activation and inflammation. Psychoneuroendocrinology 2024, 169: 107145. PMID: 39096755, PMCID: PMC11381144, DOI: 10.1016/j.psyneuen.2024.107145.Peer-Reviewed Original ResearchPremenstrual dysphoric disorderSertraline treatmentMultilevel linear modelsDysphoric disorderHypothalamic pituitary gonadalHypothalamic pituitary adrenal (HPA) axisEffects of sertraline treatmentHypothalamic pituitary adrenal (HPA) axis activityPMDD patientsPMDD statusOpen-label sertralineMildly stressful tasksPremenstrual dysphoric disorder groupDaily symptom ratingsSevere affective symptomsEffect of groupPremenstrual symptom severityMenstrual cycle phaseAssociated with higher levelsALLO levelsInflammatory markersMenstrual cycleAffective symptomsAffective disordersClinical interview